563 related articles for article (PubMed ID: 18381935)
1. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers.
Aaltonen K; Blomqvist C; Amini RM; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H
Clin Cancer Res; 2008 Apr; 14(7):1976-83. PubMed ID: 18381935
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
3. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
4. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
Armes JE; Trute L; White D; Southey MC; Hammet F; Tesoriero A; Hutchins AM; Dite GS; McCredie MR; Giles GG; Hopper JL; Venter DJ
Cancer Res; 1999 Apr; 59(8):2011-7. PubMed ID: 10213514
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Dopazo J; Rivas C; Benítez J
Breast Cancer Res Treat; 2005 Mar; 90(1):5-14. PubMed ID: 15770521
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
[TBL] [Abstract][Full Text] [Related]
7. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
8. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
10. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
11. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
[TBL] [Abstract][Full Text] [Related]
12. Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients.
Choi DH; Lee MH; Bale AE; Carter D; Haffty BG
J Clin Oncol; 2004 May; 22(9):1638-45. PubMed ID: 15117986
[TBL] [Abstract][Full Text] [Related]
13. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
14. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
15. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
16. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
[TBL] [Abstract][Full Text] [Related]
17. A comparison of bilateral breast cancers in BRCA carriers.
Weitzel JN; Robson M; Pasini B; Manoukian S; Stoppa-Lyonnet D; Lynch HT; McLennan J; Foulkes WD; Wagner T; Tung N; Ghadirian P; Olopade O; Isaacs C; Kim-Sing C; Møller P; Neuhausen SL; Metcalfe K; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1534-8. PubMed ID: 15941968
[TBL] [Abstract][Full Text] [Related]
18. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes.
Loman N; Johannsson O; Bendahl PO; Borg A; Fernö M; Olsson H
Cancer; 1998 Jul; 83(2):310-9. PubMed ID: 9669814
[TBL] [Abstract][Full Text] [Related]
19. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations.
Sensi E; Tancredi M; Aretini P; Cipollini G; Naccarato AG; Viacava P; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2003 Nov; 82(1):1-9. PubMed ID: 14672397
[TBL] [Abstract][Full Text] [Related]
20. Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E; Benítez J; Palacios J
Crit Rev Oncol Hematol; 2006 Jul; 59(1):27-39. PubMed ID: 16530420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
